Related references
Note: Only part of the references are listed.Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Robert Olson et al.
BMC CANCER (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
Anastasia Chalkidou et al.
LANCET ONCOLOGY (2020)
Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer
Philip Sutera et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A. Palma et al.
BMC CANCER (2019)
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial
Robert Olson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
Shankar Siva et al.
EUROPEAN UROLOGY (2018)
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Robert Olson et al.
BMC CANCER (2018)
Central liver toxicity after SBRT: An expanded analysis and predictive nomogram
Diego A. S. Toesca et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Predictors of Toxicity Associated With Stereotactic Body Radiation Therapy to the Central Hepatobiliary Tract
Evan C. Osmundson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
Tiziana Comito et al.
BMC CANCER (2014)
DESCRIPTIVE ANALYSIS OF OLIGOMETASTATIC LESIONS TREATED WITH CURATIVE-INTENT STEREOTACTIC BODY RADIOTHERAPY
Michael T. Milano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
An overview of hypofractionation and introduction to this issue of Seminars in Radiation Oncology
Robert D. Timmerman
SEMINARS IN RADIATION ONCOLOGY (2008)
Share Paper
